Psoriasis as an autoimmune disease

Owczarczyk‐Saczonek, Agnieszka; Placek, Waldemar

doi:10.5114/dr.2014.45121

Cited by 12 publications

(15 citation statements)

References 55 publications

(131 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moderate-to-severe psoriasis dramatically impacts the patients with reductions in physical functioning and mental health comparable to that seen in patients with cancer, arthritis, hypertension, heart disease, and diabetes 35,36 . Moreover, psoriasis is associated with multiple comorbidities including psoriatic arthritis (PsA), obesity, hypertension, malignancies, metabolic syndrome, and cardiovascular diseases 37,38 . Patients with psoriasis also have an increased risk of depression/anxiety and suicidality 39,40 .…”

Section: Discussionmentioning

confidence: 99%

Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective

Igarashi

Graham

et al. 2018

Journal of Medical Economics

View full text Add to dashboard Cite

Aim: To evaluate the cost-effectiveness of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, compared to other clinically used biologics (adalimumab, infliximab, and ustekinumab) in Japan for the treatment of moderate-to-severe psoriasis from the healthcare system (total costs) and patient co-payment (using different frequencies of drug purchase) perspectives. Methods: A decision-tree (first year)/Markov model (subsequent years), with an annual cycle, was developed. The model adopted a 5-year time horizon. Efficacy inputs were obtained from a mixedtreatment comparison analysis, and other model inputs were collected from published literature and local Japanese sources. Model outcomes included quality-adjusted life years (QALYs) and an incremental cost-effectiveness ratio (ICER) in terms of cost per QALY gained. The annual discounting rate of 2% was applied to both costs and outcomes. Results: Results for the healthcare system perspective showed that secukinumab had the highest number of quality-adjusted life years (QALYs) (4.07) vs other biologics, dominated ustekinumab and infliximab, and the ICER of secukinumab compared to adalimumab was ¥8,418,222/QALY gained. In the patient co-payment perspective with the monthly purchase of drugs, ustekinumab had the lowest co-payment cost, followed by infliximab, adalimumab, and secukinumab. In the patient co-payment perspective with a once every 3 months purchase of secukinumab and adalimumab, the co-payment costs of secukinumab, adalimumab, and ustekinumab became comparable, and infliximab had the highest co-payment cost. Limitations: Only short-term efficacy data was modeled, as there was a lack of data on long-term outcomes. Treatment sequencing was restricted to first-line biologic treatment. Drop-out rates for comparators were assumed to be equivalent to secukinumab in the absence of available data. Conclusions: Secukinumab is a cost-efficient treatment for moderate-to-severe psoriasis, providing greater health outcomes to patients at lower total costs compared to infliximab and ustekinumab, as well as comparable patient co-payment relative to other biologic treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective

Igarashi

Graham

et al. 2018

Journal of Medical Economics

View full text Add to dashboard Cite

show abstract

“…Psoriasis is an autoinflammatory disease characterized by a chronic skin inflammation with infiltrations containing T lymphocytes, neutrophils and macrophages. [1][2][3] Activated Th17 cells, formed from naive CD4 + cells under the influence of interleukin 23 (IL-23), 4 migrate to the skin, where in the presence of pro-inflammatory cytokines, such as IL-1β, they produce IL-17 4 which is known to play a key role in the development of psoriatic plaque. 5 Another protein, osteopontin (OPN), supposedly engaged in the pathogenesis of psoriasis, has a substantial role in certain physiological processes as well as in the pathogenesis of inflammatory disease, cancer and autoimmune diseases.…”

Section: Introductionmentioning

confidence: 99%

Serum concentration of osteopontin and interleukin 17 in psoriatic patients

et al. 2020

View full text Add to dashboard Cite

Background. Psoriasis is a chronic, autoinflammatory disease characterized by activation and differentiation of naive T lymphocytes towards T helper CD4 + (including Th1 and Th17) and T cytotoxic CD8 + . Osteopontin (OPN), which plays an important role in both physiological processes and inflammatory, neoplastic and autoimmune diseases, is also considered in the context of psoriasis pathogenesis. Current data indicates that OPN is a multifunctional protein involved in the modulation of Th1 and Th17 cellular responses, in stimulating keratinocyte proliferation, and in the regulation of cellular apoptosis.Objectives. The assessment of OPN and interleukin 17 (IL-17) concentrations in the peripheral blood of psoriatic patients in comparison to healthy volunteers as well as the correlations of OPN and IL-17 with the severity of psoriasis.Material and methods. The study included 107 male psoriatic patients and 41 age-matched healthy men. The serum concentrations of IL-17 and OPN were examined using the enzyme-linked immunosorbent assay (ELISA) method. The skin change severity of psoriasis was assessed using the Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), Physician Global Assessment (PGA), and Dermatology Life Quality Index (DLQI).Results. Psoriatic patients had significantly higher concentrations of OPN (31.65 ng/mL on average) than the healthy volunteers (11.42 ng/mL on average) (p < 0.001). Interleukin 17 was also higher in psoriatic patients (0.53 pg/mL on average) compared to healthy volunteers (0.09 pg/mL on average) (p < 0.001). There was no significant correlation between OPN and IL-17 concentrations in psoriatic patients and in healthy volunteers. Psoriasis severity correlated positively to IL-17 serum concentration, but not to OPN. Conclusions.Although the study did not show a relationship between OPN and IL-17 concentrations in psoriatic patients, it should be emphasized that serum concentrations were significantly higher in the patients with psoriasis compared to healthy volunteers.

show abstract

“…It induces the infiltration of Th1 cells, and the activation of APCs and endothelial cells [51]. The main source of this cytokine are T lymphocytes (mainly Th1), NK cells, NK T cells and activated macrophages in small amounts [8,36]. It is now believed that a number of inflammatory and autoimmune diseases may be associated with inadequate IFN-γ expression.…”

Section: Discussionmentioning

confidence: 99%

“…The mutual relationship between IL-12 and IFN-γ should be emphasized. Generally, IL-12 promotes the secretion of IFN-γ by T lymphocytes, and in turn IFN-γ induces the production of IL-12 in dendritic cells and/or macrophages -this is called axis IL-12/Th1/IFN-γ [8]. In addition, IL-12 is essential for the differentiation of Th1 cells, which are the main place of production of IFN-γ [8].…”

Section: Discussionmentioning

confidence: 99%

“…It is believed that IL-12 acts on naive T lymphocytes and initiates Th1 response, and IL-23 supports inflammatory reaction, which is regulated by Th1. The inflammation initiated by Th1 stimulates Th17 activity, supporting the induced inflammatory reaction [8]; T-helper 22 (Th22) lymphocytes, through IL-22, regulate the function of keratinocytes, mainly in the process of skin response to infection [9]; and IL-22 together with TNF-α, by stimulating chemokines and recruitment of neutrophils, activates metalloproteinases, which leads to the degradation of connective tissue stroma.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Analysis of molecular markers as IL-12, IL-22 and IFN-γ in correlation with a clinical course in patients with psoriasis

Kutwin

Migdalska-Sęk

Brzeziańska-Lasota

et al. 2020

Int J Occup Med Environ Health

View full text Add to dashboard Cite

As a chronic, recurrent, immunologically mediated systemic disease and a common cause of dermatological problems, psoriasis is often a subject of scientific research. Skin changes located on the hands can cause difficulties and limitations in the performance of professional activities, especially manual ones. The main role in pathogenesis is played by immunological factors-improper functioning of the components of the immune system, among others, T lymphocytes and cytokines like interleukin-12 (IL-12), interleukin-22 (IL-22) and interferon gamma (IFN-γ). Material and Methods: The obtained tissue and blood were destined for RNA isolation. The RNA was then subjected to a reverse transcription reaction. The relative gene expression level was evaluated by the real-time polymerase chain reaction for IL-12B, IL-22 and IFN-γ genes, and presented as the relative quantification (RQ) value, relative to the reference gene GAPDH. In addition, a correlation analysis of the expression level of selected genes with the clinical course of the disease, as assessed by the Psoriasis Area and Severity Index (PASI), the Body Surface Area (BSA) and the Dermatology Life Quality Index (DLQI) scores was performed. Results: Statistical analysis confirmed a significant increase in RQ values for IL-12B, IL-22 and IFN-γ in the group of psoriatic patients vs. the control group. A positive correlation was also found between BSA and PASI and RQ for the IL-12B gene. Conclusions: Increased expression levels of IL-12B, IL-22 and IFN-γ genes in psoriatic skin confirm that selected cytokines play an important role in the initiation and sustenance of psoriasis.

show abstract

Psoriasis as an autoimmune disease

Cited by 12 publications

References 55 publications

Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective

Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective

Serum concentration of osteopontin and interleukin 17 in psoriatic patients

Analysis of molecular markers as IL-12, IL-22 and IFN-γ in correlation with a clinical course in patients with psoriasis

Contact Info

Product

Resources

About